Asia-Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. A significant rise in cancer prevalence is one of the major factors accelerating the demand for peripheral neuropathy treatment in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences in India was nearly 1.1 million in 2018. Chemotherapy is most often used for cancer treatment, which is significantly associated with the risk of developing chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy is used to destroy rapidly growing cancer cells in the body. The condition has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. CIPN is normally treated with anticonvulsants, analgesics, and antidepressants. Topical agents including lidocaine are often used, and opioids can also be used in cases that involve extreme pain.
To Request a Sample of our Report on Asia-Pacific Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment-market
Scope of the Asia-Pacific Peripheral Neuropathy Treatment Market
Market Coverage
· Market number available for 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Type and Application
· Countries Covered- China, India, Japan, and Rest of Asia-Pacific
· Competitive Landscape- Alembic Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Company, Ltd., and Pfizer Inc.
Recent Strategic Initiatives in the Asia-Pacific Peripheral Neuropathy Treatment Market
· In April 2019, Daiichi Sankyo Company, Ltd. declared the launch of Tarlige tablets for pain treatment in Japan. In Japan 2019, ?2? ligand drug was approved in Japan for marketing based on phase 3 clinical trials results performed in Asia, for patients suffering from diabetic peripheral neuropathic pain, postherpetic neuralgia (PHN), for the treatment of peripheral neuropathic pain.
· In July 2019, Cipla declared that InvaGen Pharmaceuticals, its subsidiary gained US approval for Pregabalin Capsules, which is intended for neuropathic pain management associated with some illnesses. InvaGen gained approval from the US FDA for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg.
Key questions addressed by the report
· What is the market growth rate?
· Which segment dominates the market in the base year?
· Which segment will project the fastest growth in the market?
· How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Peripheral Neuropathy Treatment Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-peripheral-neuropathy-treatment-market
Asia-Pacific Peripheral Neuropathy Treatment Market-Segmentation
By Type
· Antidepressants
· Pain Relievers
· Antiseizure
· Others
By Application
· Diabetes
· Chemotherapy-Induced
· Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
